Business Description
Cellectar Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US15117F5008
Total Employee Number:
11Description
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.46 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 0.46 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 58.5 | |||||
3-Year EPS without NRI Growth Rate | 61.4 | |||||
3-Year FCF Growth Rate | 56.6 | |||||
3-Year Book Growth Rate | -58.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 61.85 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.9 | |||||
Quick Ratio | 1.9 | |||||
Cash Ratio | 1.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -138.4 | |||||
Shareholder Yield % | -0.98 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -304.63 | |||||
ROA % | -147.89 | |||||
ROIC % | -946.29 | |||||
3-Year ROIIC % | -102.4 | |||||
ROC (Joel Greenblatt) % | -1903.52 | |||||
ROCE % | -254.02 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.89 | |||||
Price-to-Tangible-Book | 4.19 | |||||
EV-to-EBIT | -0.64 | |||||
EV-to-EBITDA | -0.64 | |||||
EV-to-Forward-Revenue | 2.23 | |||||
EV-to-FCF | -0.77 | |||||
| Price-to-Net-Current-Asset-Value | 12.58 | |||||
| Price-to-Net-Cash | 25.15 | |||||
Earnings Yield (Greenblatt) % | -156.25 | |||||
FCF Yield % | -90.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cellectar Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -6.357 | ||
| Beta | -0.0492 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.8 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 0.2515 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.2515 - 0.2515 | ||
| Shares Outstanding (Mil) | 7.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cellectar Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cellectar Biosciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:30 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 28 days | ||
| General meeting for 2026 | 2026-07-07 10:00 | 0.25 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 08:30 | 0.25 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.25 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-04 08:30 | 0.25 (+0.00%) | ||
| Annual report for 2025 | 2026-03-04 | 0.25 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 0.25 (+0.00%) |
Show
Entries
Cellectar Biosciences Inc Frequently Asked Questions
What is Cellectar Biosciences Inc(FRA:NV40)'s stock price today?
The current price of FRA:NV40 is €0.25. The 52 week high of FRA:NV40 is €0.25 and 52 week low is €0.25.
When is next earnings date of Cellectar Biosciences Inc(FRA:NV40)?
The next earnings date of Cellectar Biosciences Inc(FRA:NV40) is 2026-08-14 Est..
Does Cellectar Biosciences Inc(FRA:NV40) pay dividends? If so, how much?
Cellectar Biosciences Inc(FRA:NV40) does not pay dividend.
Press Release
Articles on Cellectar Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers